A new two-drug combo for advanced stomach cancer after first treatment
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of paclitaxel polymeric micelles and fruquintinib capsules as a second-line treatment for patients with advanced gastric cancer whose first-line therapy with oxaliplatin and fluorouracil has stopped working. The goal is to see if this new drug combination can shrink tumors and how safe it is.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have advanced stomach cancer that was confirmed by a biopsy and has continued to grow after treatment with oxaliplatin and fluorouracil.
- You have at least one tumor that can be measured on a scan.
- You are able to care for yourself (ECOG score 0 or 1).
- Your major organs (bone marrow, liver, kidneys, heart) are working well enough, as shown by blood and heart tests.
- You have not had other cancer treatments (chemo, radiation, or another study drug) within 2–4 weeks before starting this trial, and any side effects from previous treatments have mostly gone away.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two treatments for advanced stomach cancer: fruquintinib plus paclitaxel versus ramucirumab plus paclitaxel. It aims to see which combination works better for patients who have already received certain therapies.
This trial tests a combination of two oral drugs (paclitaxel and fruquintinib) for advanced stomach cancer that has already been treated with one round of chemotherapy. The goal is to see if this combination helps control the cancer better than other standard second-line treatments.
This trial tests a combination of two drugs (fruquintinib and albumin-paclitaxel) with or without an immunotherapy drug (PD-1 antibody) as a second-line treatment for advanced stomach cancer. It aims to see if adding immunotherapy improves outcomes for people who have already received immunotherapy before.
This trial tests a combination of three drugs—cadonilimab, fruquintinib, and albumin-bound paclitaxel—as a second treatment for advanced stomach cancer. It may be an option if your first treatment stopped working and you have not had certain types of prior therapy.
This trial tests a combination of targeted therapy (fruquintinib), chemotherapy (nab-paclitaxel), and two immunotherapies (iparomlimab and tuvonralimab) for people with advanced stomach or gastroesophageal junction cancer whose first treatment with a PD-1/PD-L1 inhibitor stopped working. The goal is to see if this new combination can shrink tumors and improve outcomes.
This trial tests a combination of two drugs, fruquintinib and TAS102, for people with advanced stomach cancer that has stopped responding to at least one prior chemotherapy. The goal is to see if this new combination can help shrink tumors or slow the cancer's growth.
Hear when a new Advanced Gastric Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.